A Randomized Multicenter Study to Compare Tacrolimus and MMF With Tacrolimus and Rapamycin in Patients After Renal Transplantation

University Hospital Muenster1 site in 1 country190 target enrollmentJanuary 2002

ConditionsKidney Transplantation

DrugsSirolimus

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Kidney Transplantation
Sponsor: University Hospital Muenster
Enrollment: 190
Locations: 1
Primary Endpoint: - time to first biopsy proven acute rejection episode at month 12
Last Updated: 20 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To study the efficacy and safety of the administration of Tacrolimus in combination with Sirolimus for the prevention of acute rejection in patients after renal transplantation

Detailed Description

Basic randomized clinical trial (multicentre) in primary KTX to assess the safety and efficacy of a tac/rapa vs a tac/MMF regimen. Tac trough levels in accordance with current standards in both arms. Steroids to be used to individual centre protocol. Rapa trough levels will be adjusted to 5-10 ng/ml. Up to now only few data (primate and clinical) on tac/rap combinations available.

Registry

clinicaltrials.gov

Start Date

January 2002

End Date

June 2005

Last Updated

20 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

University Hospital Muenster

Eligibility Criteria

Inclusion Criteria

•first kidney transplantation
•re-transplantation
•non-related living donor transplantation
•patients \> 18 years
•patients have given their written consent after being informed
•female patients in the age of parity must consent to an effective birth control and submit a negative pregnancy test

Exclusion Criteria

•related living donation
•patients with known HIV-anamnesis
•patients who need systemically administered immunosuppression for another indication than the prophylaxis of kidney graft rejection
•patients with present malignant disease
•patients with clinically significant, uncontrolled infectional disease and/or severe diarrhea, vomiting or active gastric ulcer
•patients who haven taken part in a clinical study in the past 28 days and/or receive (received) medication which is not licensed by the responsible health authority
•other reasons which depend on the assessment of the physician

Outcomes

Primary Outcomes

- time to first biopsy proven acute rejection episode at month 12

- graft failure at month 12

- discontinuation of study medication at month 12

Secondary Outcomes

- patient and graft survival at month 12
- incidence and severity of biopsy proven acute rejection episodes and incidence of steroid-resistant acute rejection episodes at month 12
- Renal function at month 12 (S-creatinine, Cockgroft-Gault clearance)
- incidence and severity of infections at month 12
- incidence of adverse events at month 12